PubMed:32471903 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":52,"end":60},"obj":"SP_7"},{"id":"T2","span":{"begin":64,"end":70},"obj":"NCBITaxon:9606"},{"id":"T3","span":{"begin":109,"end":117},"obj":"SP_7"},{"id":"T4","span":{"begin":180,"end":196},"obj":"SP_7"},{"id":"T5","span":{"begin":209,"end":215},"obj":"NCBITaxon:9606"},{"id":"T6","span":{"begin":338,"end":346},"obj":"SP_7"},{"id":"T7","span":{"begin":373,"end":379},"obj":"NCBITaxon:9606"},{"id":"T8","span":{"begin":428,"end":439},"obj":"NCBITaxon:1"},{"id":"T9","span":{"begin":467,"end":475},"obj":"SP_7"},{"id":"T10","span":{"begin":485,"end":493},"obj":"SP_7"},{"id":"T11","span":{"begin":940,"end":944},"obj":"GO:0016265"},{"id":"T12","span":{"begin":980,"end":990},"obj":"CHEBI:8382"},{"id":"T13","span":{"begin":980,"end":990},"obj":"CHEBI:8382"},{"id":"T14","span":{"begin":1128,"end":1146},"obj":"CHEBI:35842"},{"id":"T15","span":{"begin":1128,"end":1146},"obj":"CHEBI:35842"},{"id":"T16","span":{"begin":1207,"end":1217},"obj":"CHEBI:66921"},{"id":"T17","span":{"begin":1207,"end":1217},"obj":"CHEBI:66921"},{"id":"T18","span":{"begin":1337,"end":1373},"obj":"CHEBI:35475"},{"id":"T19","span":{"begin":1337,"end":1373},"obj":"CHEBI:35475"},{"id":"T20","span":{"begin":1375,"end":1380},"obj":"CHEBI:35472"},{"id":"T21","span":{"begin":1375,"end":1380},"obj":"CHEBI:35472"},{"id":"T22","span":{"begin":1488,"end":1497},"obj":"CHEBI:35222"},{"id":"T23","span":{"begin":1488,"end":1497},"obj":"CHEBI:35222"},{"id":"T24","span":{"begin":1504,"end":1507},"obj":"PR:000000134"},{"id":"T25","span":{"begin":1625,"end":1637},"obj":"CHEBI:35718"},{"id":"T26","span":{"begin":1625,"end":1637},"obj":"CHEBI:35718"},{"id":"T27","span":{"begin":1714,"end":1728},"obj":"CHEBI:24261"},{"id":"T28","span":{"begin":1714,"end":1728},"obj":"CHEBI:24261"},{"id":"T29","span":{"begin":1813,"end":1816},"obj":"PR:000000134"},{"id":"T30","span":{"begin":1925,"end":1931},"obj":"CHEBI:35472"},{"id":"T31","span":{"begin":1925,"end":1931},"obj":"CHEBI:35472"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.\nOBJECTIVES: COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.\nMETHODS: Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.\nRESULTS: A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.\nCONCLUSIONS: We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation."}

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":175},"obj":"Sentence"},{"id":"T2","span":{"begin":176,"end":265},"obj":"Sentence"},{"id":"T3","span":{"begin":266,"end":403},"obj":"Sentence"},{"id":"T4","span":{"begin":404,"end":412},"obj":"Sentence"},{"id":"T5","span":{"begin":413,"end":532},"obj":"Sentence"},{"id":"T6","span":{"begin":533,"end":564},"obj":"Sentence"},{"id":"T7","span":{"begin":565,"end":655},"obj":"Sentence"},{"id":"T8","span":{"begin":656,"end":810},"obj":"Sentence"},{"id":"T9","span":{"begin":811,"end":819},"obj":"Sentence"},{"id":"T10","span":{"begin":820,"end":873},"obj":"Sentence"},{"id":"T11","span":{"begin":874,"end":945},"obj":"Sentence"},{"id":"T12","span":{"begin":946,"end":1089},"obj":"Sentence"},{"id":"T13","span":{"begin":1090,"end":1336},"obj":"Sentence"},{"id":"T14","span":{"begin":1337,"end":1464},"obj":"Sentence"},{"id":"T15","span":{"begin":1465,"end":1686},"obj":"Sentence"},{"id":"T16","span":{"begin":1687,"end":1699},"obj":"Sentence"},{"id":"T17","span":{"begin":1700,"end":1893},"obj":"Sentence"},{"id":"T18","span":{"begin":1894,"end":1987},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":175},"obj":"Sentence"},{"id":"T2","span":{"begin":176,"end":265},"obj":"Sentence"},{"id":"T3","span":{"begin":266,"end":403},"obj":"Sentence"},{"id":"T4","span":{"begin":404,"end":412},"obj":"Sentence"},{"id":"T5","span":{"begin":413,"end":532},"obj":"Sentence"},{"id":"T6","span":{"begin":533,"end":564},"obj":"Sentence"},{"id":"T7","span":{"begin":565,"end":655},"obj":"Sentence"},{"id":"T8","span":{"begin":656,"end":810},"obj":"Sentence"},{"id":"T9","span":{"begin":811,"end":819},"obj":"Sentence"},{"id":"T10","span":{"begin":820,"end":873},"obj":"Sentence"},{"id":"T11","span":{"begin":874,"end":945},"obj":"Sentence"},{"id":"T12","span":{"begin":946,"end":1089},"obj":"Sentence"},{"id":"T13","span":{"begin":1090,"end":1336},"obj":"Sentence"},{"id":"T14","span":{"begin":1337,"end":1464},"obj":"Sentence"},{"id":"T15","span":{"begin":1465,"end":1686},"obj":"Sentence"},{"id":"T16","span":{"begin":1687,"end":1699},"obj":"Sentence"},{"id":"T17","span":{"begin":1700,"end":1893},"obj":"Sentence"},{"id":"T18","span":{"begin":1894,"end":1987},"obj":"Sentence"}],"text":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.\nOBJECTIVES: COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.\nMETHODS: Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.\nRESULTS: A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.\nCONCLUSIONS: We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation."}

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":1465,"end":1471},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.\nOBJECTIVES: COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.\nMETHODS: Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.\nRESULTS: A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.\nCONCLUSIONS: We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation."}